Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Hormone-Refractory Prostate Cancer

NCT00140400 is registered in ClinicalTrials.gov with Cell Genesys as lead sponsor.

NCT NCT00140400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00140400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Hormone-Refractory Prostate Cancer
Lead sponsor
Cell Genesys
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 1999
Completion date
January 31, 2001
Enrollment
50
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer